NCT06726148 - Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Biotech Hunter

Enrollment

280

Participants

Timeline

Start Date

April 3, 2025

Primary Completion Date

September 25, 2028

Study Completion Date

September 25, 2028

Conditions

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors

Interventions

DRUG

ECI830

Experimental

DRUG

ribociclib

Approved medication

DRUG

fulvestrant

Approved medication

Trial Locations (16)

704

RECRUITING

Novartis Investigative Site, Tainan City

3004

RECRUITING

Novartis Investigative Site, Melbourne

3168

RECRUITING

Novartis Investigative Site, Clayton

10017

RECRUITING

Memorial Sloan Kettering, New York

33901

RECRUITING

Florida Cancer Specialists, Fort Myers

37203

RECRUITING

SCRI Oncology Partners, Nashville

63110

RECRUITING

WA Uni School Of Med, St Louis

77030

RECRUITING

MD Anderson Cancer Center Uni of Te, Houston

90095

RECRUITING

University of California LA, Los Angeles

119074

RECRUITING

Novartis Investigative Site, Singapore

3109601

RECRUITING

Novartis Investigative Site, Haifa

6423906

RECRUITING

Novartis Investigative Site, Tel Aviv

02115

RECRUITING

Dana Farber Cancer Institute, Boston

M5G 2M9

RECRUITING

Novartis Investigative Site, Toronto

104 0045

RECRUITING

Novartis Investigative Site, Chuo Ku

03080

RECRUITING

Novartis Investigative Site, Seoul